title: Two pioneering osteoporosis drugs finally approach approval.
authors.forename: Ken
authors.initials: K
authors.lastname: Garber
mesh_terms: D048868:Adaptor Proteins, Signal Transducing; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D019485:Bone Morphogenetic Proteins / Q000037:antagonists & inhibitors; D056657:Cathepsin K / Q000037:antagonists & inhibitors; D005819:Genetic Markers; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D000911:Antibodies, Monoclonal; D001713:Biphenyl Compounds; D050071:Bone Density Conservation Agents; D019485:Bone Morphogenetic Proteins; D005819:Genetic Markers; C422903:SOST protein, human; C557282:romosozumab; D056657:Cathepsin K; C527128:odanacatib